An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus Vulgaris

Trial Profile

An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus Vulgaris

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Efgartigimod (Primary)
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept
  • Sponsors argenx
  • Most Recent Events

    • 30 Oct 2017 According to an argenx media release, interim results from this trial are expected during the second half of 2018.
    • 28 Sep 2017 New trial record
    • 26 Sep 2017 According to an argenx media release, the study design will be presented during a PV Key Opinion Leader event in New York on November 10, 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top